Latest Headlines

1. PathAI And MedStar Health Announce Partnership To Deploy The AISight® Dx Digital Pathology Platform And Advanced AI Applications 4/7/2026

   PathAI, a leading provider of AI-powered pathology solutions, and MedStar Health, a leading health system headquartered in Columbia, Maryland, today announced a multi-year strategic collaboration to deploy PathAI’s AISight® Dx1 Digital Pathology Platform and various AI algorithm products across the multi-site network.

2. Plus Therapeutics Receives AMA PLA Code For CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement And U.S. Commercial Adoption 4/7/2026

   Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the American Medical Association (AMA) has approved a new, Proprietary Laboratory Analyses (PLA) Current Procedural Terminology (CPT) code for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test.

3. UCLA Researchers Develop Low-Cost Blood Test To Detect Multiple Cancers And Other Diseases From A Single Sample 4/6/2026

   UCLA scientists have developed a simple and cost-effective blood test that, in early studies, shows promise in detecting multiple cancers, various liver conditions and organ abnormalities simultaneously by analyzing DNA fragments circulating in the bloodstream.

4. GeneProof Announces CMV IVDR Launch On The myCROBE™ Fully Automated System For Transplant Care 4/2/2026

   GeneProof, a molecular diagnostics manufacturer and part of NuvinkaDx, announced several significant product and regulatory milestones.

5. Cancer Is Striking Earlier - Superpower And GRAIL Are Partnering To Expand Early Detection 4/1/2026

   Superpower, the first all-in-one proactive health platform, announced a strategic partnership with GRAIL, Inc. (Nasdaq: GRAL) to bring members access to the Galleri® multi-cancer early detection (MCED) test.

6. Breaking The PCR-Only Barrier: Dual 510(k) Clearance And CLIA-Waiver Establish FINDER As The First Molecular Point-Of-Care Platform With Multifunctional Capabilities 3/31/2026

   Baebies announced FDA 510(k) clearance and CLIA-waiver approval for the FINDER® Flu A&B/SARS-CoV-2 Test, an ultra-rapid RT-PCR assay on the FINDER platform.

7. Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM 3/31/2026

   Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before.

8. LabConnect Launches SampleGISTICS® 2.0 To Digitize Clinical Trial Sample Capture 3/31/2026

   LabConnect, a global provider of central laboratory services and functional service provider solutions for clinical trials, today announced the launch of SampleGISTICS® 2.0, an application that enables clinical research sites to scan, record and transmit participant sample information.

9. Takara Bio USA And Hamilton Company Partner To Automate NGS Library Preparation 3/30/2026

   Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company announced a development and co-marketing agreement to deliver integrated, automated next-generation sequencing (NGS) library preparation workflows to laboratories worldwide.

10. Ataraxis AI Launches Ataraxis Breast CTX, The First Predictive AI Test Estimating Individualized Chemotherapy Benefit In Breast Cancer 3/30/2026

    Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced Ataraxis Breast CTX, a new predictive capability within its Ataraxis Breast platform, designed to help estimate individualized chemotherapy benefit in breast cancer patients.